Bio-Rad Laboratories, Inc. Announces Completion of Exchange Offer of Its 6.125% Senior Subordinated Notes due 2014 for Registered Notes HERCULES, Calif., June 1 /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc. (Amex: BIO; BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has completed its offer to exchange (the "Exchange Offer") up to $200 million aggregate principal amount of its 6.125% Senior Subordinated Notes due 2014 which have been registered under the Securities Act of 1933, as amended for any and all of its outstanding 6.125% Senior Subordinated Notes due 2014 which were issued in a private placement (the "Private Notes"). All of the $200 million aggregate principal amount of the Private Notes were tendered and received prior to expiration of the Exchange Offer at 5:00 p.m., New York City time, on May 31, 2005. This announcement is not an offer to exchange, or a solicitation of an offer to exchange, with respect to the Private Notes. The Exchange Offer was made solely by the prospectus dated May 2, 2005. Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices. DATASOURCE: Bio-Rad Laboratories, Inc. CONTACT: Christine Tsingos, Vice President and Chief Financial Officer, or Ron Hutton, Treasurer, +1-510-724-7000, or , both of Bio-Rad Laboratories, Inc. Web site: http://www.bio-rad.com/

Copyright